2005
DOI: 10.1016/s0076-6879(05)91004-5
|View full text |Cite
|
Sign up to set email alerts
|

The Liposomal Formulation of Doxorubicin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
244
0
9

Year Published

2006
2006
2018
2018

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 374 publications
(261 citation statements)
references
References 36 publications
8
244
0
9
Order By: Relevance
“…This approach resulted in a decrease in binding of the GBM with the liposomes. activity of the liposomal doxorubicin is sensitive to vesicle size, and the liposomes in this size range can readily release their contents within the cells (45), which is consistent with our observations in this study.…”
Section: Discussionsupporting
confidence: 92%
“…This approach resulted in a decrease in binding of the GBM with the liposomes. activity of the liposomal doxorubicin is sensitive to vesicle size, and the liposomes in this size range can readily release their contents within the cells (45), which is consistent with our observations in this study.…”
Section: Discussionsupporting
confidence: 92%
“…However, its clinical application is limited by cardiac hypertrophy, a dose-limiting side effect arising from the formation of free-radicals and lipid peroxidation (32). The design of doxorubicin-loaded nanocarriers (i.e., liposomes or nanoparticles) has gained increasing interest as a mean of improving the treatment of neoplastic diseases and reducing the drug-mediated cardiotoxicity (16,(33)(34)(35). However, the need to surface-functionalize these nanodevices with PEG raises toxicological issues because of the previously mentioned biodegradability and safety concerns of PEG (23,36).…”
Section: E)mentioning
confidence: 99%
“…One of the approaches to avoid DXR-related toxicity is to encapsulate it into appropriate drug carriers, which provides a change in the in-vivo distribution of DXR, resulting in reduced DXR levels in the heart (Abraham et al, 2005). DXR encapsulated in PEG liposome, known as Doxil in the United States, has revealed an increased therapeutic efficacy and reduced cardiotoxicity compared to free DXR (Working and Dayan, 1996;Gabizon et al, 2003).…”
Section: Introductionmentioning
confidence: 99%